

# St Jude Medical-Biocor bovine pericardial bioprosthesis: long-term survival

*Bioprótese valvar de pericárdio bovino St Jude Medical-Biocor: sobrevida tardia*

Felipe W. DE BACCO<sup>1</sup>, João Ricardo M. SANT'ANNA<sup>2</sup>, Roberto T. SANT'ANNA<sup>1</sup>, Paulo R. PRATES<sup>3</sup>, Renato A. K. KALIL<sup>4</sup>, Ivo A. NESRALLA<sup>5</sup>

RBCCV 44205-781

## Abstract

**Objective:** The objective of this work is to present long-term results of valve replacement using SJM-Biocor™ bovine pericardial bioprostheses.

**Methods:** From 1992 to 2000, 304 patients were discharged from hospital after bioprosthesis implantation. Ages ranged from 15 to 83 years (mean:  $60.6 \pm 14.3$  years) and 50.3% were male. Patient deaths and events related to bioprosthesis (infection, thromboembolism and structural failure) were considered for estimation of cumulative probability of survival and event-free survival.

**Results:** Total follow-up was 931.0 patients-year. During follow-up there were 28 (9.2%) deaths. Causes were bioprosthesis failure in five (1.6%), cardiac in seven (2.3%), non-cardiac in four (1.3%), and unknown in 12 (3.9%) patients. Events related to bioprosthesis were: endocarditis: 18 (5.9%), fibrocalcific degeneration: 15 (4.9%), thromboembolism: three (1.0%), hemolysis: one (0.3%). Bioprosthesis dysfunctions resulted in 16 (5.2%) reoperations due to fibrocalcific degeneration (nine), endocarditis (six) and thromboembolism (one). Probability of survival was higher in the young population (< 40 years, n=35) when compared to the older group (> 60 year, n=187):  $82.0 \pm 13.3\%$  vs.  $58.8 \pm 13.6\%$  in the 9<sup>th</sup> year. Event-free survival was  $77.5 \pm$

$3.7\%$  for 5<sup>th</sup> year and  $40.2 \pm 9.0\%$  for 10<sup>th</sup> year. Overall estimative of structural failure for a SJM-Biocor™ was 5% in 5<sup>th</sup> year increasing to 20% in the 10<sup>th</sup> year. In the aortic position the values were zero and 8%, respectively. Considering current clinical conditions, 88.5% are in NYHA class I, 9.1% in class II and 2.3% in class III.

**Conclusions:** SJM-Biocor™ bovine pericardial bioprostheses resulted in satisfactory survival of patients, related to low prevalence of bioprosthesis dysfunction.

**Descriptors:** Bioprosthesis. Heart valve prosthesis. Heart valves.

## Resumo

**Objetivo:** Nosso objetivo é apresentar resultados a longo prazo da substituição valvar por bioprótese de pericárdio bovino SJM-Biocor™.

**Método:** Entre 1992 e 2000, tiveram alta hospitalar, após substituição valvar por bioprótese de pericárdio bovino SJM-Biocor™ 304 pacientes. Idades eram de 15 a 83 anos (média:  $60,6 \pm 14,3$ ), sendo 50,3% do sexo masculino. Pacientes tiveram situação clínica atualizada e análise atuarial foi empregada no cálculo da sobrevida simples e livre de eventos.

1 - Scientific initiation scholar of CNPq-IC/FUC.

2 - Cardiovascular surgeon of the Cardiology Institute of RS/FUC. Professor of post graduation, PhD of the Fundação Universitária de Cardiologia (FUC-RS)

3 - Surgeon Head of Surgical Block of the Cardiology Institute do RS/FUC.

4 - Professor Head of Cardiology Department of FFFCMPA. Member of Coordination Committee and Professor of post graduation of Fundação Universitária de Cardiologia (FUC-RS)

5 - Head of Cardiovascular Surgery Department of the Cardiology Institute do RS/FUC.

Work performed in the Cardiovascular Surgery Service - Cardiology Institute of Rio Grande do Sul - Fundação Universitária de Cardiologia, Porto Alegre, RS.

Correspondence address:

Instituto de Cardiologia do Rio Grande do Sul / F.U.C.

Av. Princesa Isabel, 395. Porto Alegre, RS. CEP: 90620-001.

E-mail: santanna@cardiologia.org.br

Article received in July, 2005  
Article accepted in November, 2005

**Resultados:** Em um seguimento total de 931,0 pacientes-ano, ocorreram 28 (9,2%) óbitos tardios, sendo cinco (1,6%) relacionados à bioprótese, sete (2,3%) cardíacos, quatro (1,3%) não-cardíacos e 12 (3,9%) de causa desconhecida. Eventos de bioprótese foram: endocardite: 18 (5,9%), degeneração fibrocálcica: 15 (4,9%), tromboembolismo: três (1,0%), hemólise: um (0,3%). Disfunção de bioprótese resultou em 16 (5,2%) reoperações, por degeneração fibrocálcica (nove), endocardite (seis) e tromboembolismo (um). Probabilidade de sobrevida foi 86,3±3,4%, no 5º, e 69,3±9,0%, no 10º ano pós-operatório. Idade jovem (<40 anos, n= 35) mostrou maior sobrevida em relação à mais idosa (>60 anos, n=187): 82,0±13,3% vs 58,8±13,6%, no 9º ano. Sobrevida

livre de eventos foi 77,5±3,7%, no 5º, e 40,2±9,0%, no 10º ano. Probabilidade de falência estrutural de bioprótese foi 5%, no 5º ano, e 20%, no 10º; em aórticos, zero e 8%, respectivamente. A classe funcional (NYHA) atual é I para 88,5%, II para 9,1% e III para 2,4% dos pacientes.

**Conclusão:** Implante de bioprótese de pericárdio bovino SJM-Biocor™ resulta em satisfatória perspectiva de sobrevida dos pacientes com doença valvar e apresenta baixa prevalência de disfunção de prótese.

**Descritores:** Bioprótese. Prótese das valvas cardíacas. Valvas cardíacas.

## INTRODUCTION

Implantation of biological prosthesis during heart valve replacement reduces the risk of thromboembolic events and avoids specific anticoagulation therapy [1]. The improvement in the quality of life is set against its durability, which is the reason for several changes in the preparation of biological tissues and prosthesis projects [2-5]. The concept of bioprosthesis, introduced by Carpentier et al. [6], allows favorable long-term results with heterologous prostheses manufactured from porcine aortic valves [7].

Bovine pericardial bioprosthesis were introduced by Ionesco, aiming at improving the durability and hemodynamical performance compared to porcine aortic valve bioprosthesis [8,9]. Initial tests in a pulse simulator identified the possibility of early structural failure [10], but changes in the project and in the technique of tissue preparation gave favorable hemodynamic and clinical results [11,12]. Their use in Brazil was publicized by Braile et al. [13] and the St Jude Medical-Biocor™ prosthesis (SJM-Biocor™) was introduced in 1982 [14]. This model incorporates structural changes in the pericardial membrane that give a better durability and a satisfactory hemodynamical result [6].

The aim of the current study is to present the results observed in patients who underwent valve replacement with the implantation of SJM-Biocor™ bovine pericardial bioprosthesis.

## METHOD

### Patients

From November 1992 to December 2000, 358 consecutive patients were submitted to the implantation of, at least one, SJM-Biocor™ bovine pericardial prosthesis. From these, 304 patients, who were discharged from the Institute of Cardiology of Rio Grande do Sul / Fundação Universitária de Cardiologia, were included in this study. One hundred and fifty-one (49.6%) patients were female and 153 (50.3%) were male. Ages ranged from 15 to 83 years with a mean and

standard deviation of 60.6 ± 14.3 years. Thirty-five (11.5%) patients were under 40 years old, 82 (27.0%) between 40 and 60 years old and 187 (61.5%) patients were over 60 years old.

The functional class according to the criteria of the New York Heart Association (NYHA) was II in 29.9%, III in 48.0% and IV in 22.0% of the cases.

The etiology of the valve injury was idiopathic in 125 (41.1%), rheumatic in 92 (30.3%), myxomatosis in 28 (9.2%), ischemic in 21 (6.9%), Marfan's syndrome in 11 (3.6%), endocarditis in 11 (3.6%) and congenital in four patients (1.3%); 12 (4.0%) patients presented with dysfunction of bioprosthesis.

From the total, 78 (25.6%) patients had been submitted to prior heart valve surgery. The total and mean follow-ups were 931.0 patient-years and 3.8 ± 2.0 patient-years, respectively.

### Methods

Surgical procedures were performed according to the accepted routines, including the use of cardiopulmonary bypasses, myocardial preservation using hypothermic crystalloid cardioplegia and moderate hypothermia (from 32° to 28° C).

In respect to the site of implantation, 172 (56.6%) patients received isolated aortic valves, 109 (35.9%) isolated mitral valves, 20 (6.6%) mitral-aortic valves and three (1.0%) tricuspid valves.

Associated heart procedures occurred in 116 (38.1%) patients, including coronary artery bypass grafting surgery in 67 (22.0%), tricuspid repair in 16 (5.2%), mitral repair in nine (2.9%), repair of congenital defects in seven (2.3%) and the Cox-Maze surgery in one (0.3%).

After surgery the patients were treated in the recovery room (intensive care unit) for a minimum of 48 hours. Hospital discharge occurred after the 5<sup>th</sup> postoperative day and oral anticoagulation therapy was not routinely prescribed; this was indicated in cases of chronic atrial fibrillation, greatly enlarged left atria or in patients with mechanical valve prostheses. Prophylactic antibiotic therapy for bacterial endocarditis was used [15].

After hospital discharge, the patients were referred to

an assistant physician or were followed up in the outpatients' clinic of the Institution. The clinical situation of each consultation was registered on the patient's record card, as were clinical or significant surgical events [16]. For patients from other institutions, direct contact was made with the referring physicians, aiming at obtaining the patient's postoperative history and after, up-to-date information on the patient.

This study was approved by Ethics Research Committee of the Institute of Cardiology of Rio Grande do Sul.

### Events

Important events related to the bioprostheses included fibrocalcific degeneration, bioprosthetic thromboses with or without peripheral embolic events, peri-valve fistulae and infections (endocarditis, even without identifying the infectious agent).

Surgical events included redo heart surgeries due to failure of the bioprostheses or other reasons (such as replacement of another heart valve or coronary artery bypass grafting surgery).

Deaths were classified as attributable to the bioprosthesis (for example thrombosis, endocarditis or dysfunction resulting in heart failure implicating the surgery or not), caused by heart disease (arrhythmia or heart failure not related to the failure of the bioprosthesis) or of non-heart causes (due to a systemic disease such as neoplasia).

### Data analysis

The late mortality, survival rate (for all patients and according to classification in demographic and operative characteristics such as age, gender, etiology of the injury and position of the valve implant), event-free survival (in which events related to the bioprosthesis were associated to deaths), the durability of the bioprosthesis (considering failure related to the bioprosthesis) and the probability of structural failure were considered. Clinical evolution, considering changes in the functional class according to the NYHA criteria, was also evaluated.

The data are shown in tables of contingency and statistically analyzed using the actuarial method [17] and the Student t-test, chi-square and Kaplan-Meier tests in the SPSS computer program. Quantitative values are expressed as means  $\pm$  standard deviations. The accepted significance level, critical  $\alpha$ , was 5% ( $p$ -value  $< 0.05$ ). Aiming at stressing the long-term results of the bioprostheses being studied, the actuarial curves were set up without taking into account hospital morbimortality that is, from the moment of hospital discharge, as events in this period are predominantly caused by heart failure, not related to the bioprosthesis. To include the effect of immediate mortality in the long-term results, it is necessary to multiply the long-term survival, at any point on the curve, by a specific index (SI) for each subgroup that

is assessed. This index results from the immediate mortality specific to each subgroup of patients. Thus, the immediate mortality of the entire sample studied (15.0%) gives a SI of 0.85. The SIs of the subgroups are 0.89 for aortic patients, 0.8 for mitral patients, 0.9 for under 40-year-olds, 0.83 for patients between 40 and 60 years and 0.85 for over 60-year-olds. The immediate mortality does not exert any influence on the durability curves, when considering events related to the bioprosthesis alone, as no events occurred before discharge from hospital.

## RESULTS

### Mortality and morbidity

The immediate mortality was 15.0% without any deaths related to bioprostheses. In the follow-up, 28 deaths occurred (3.0% per patient-year), with 5 (0.5% per patient-year) related to bioprostheses (endocarditis: two; CVA/thromboembolism: two; and bioprosthesis dysfunction: one), seven (0.7% per patient-year) due to other heart problems (heart failure: three; ventricular arrhythmia: three; acute myocardial infarction: one), four (0.4% per patient-year) due to non-heart diseases (neoplasia: three; sepsis: one) and 12 (1.2% per patient-year) of unknown causes.

Events related to the bioprostheses included endocarditis: 18 (1.9% per patient-year) episodes in 17 patients; fibrocalcific degeneration/rupture: 15 (1.6% per patient-year), with only one case of rupture; thromboembolism: three (0.3% per patient-year); hemolysis: one (0.1% per patient-year). One case of a fistula after valve replacement was reported.

The patients who suffered from fibrocalcific degeneration or rupture had a mean age of  $46.5 \pm 11.6$  years; a mean age lower than the patients without this complication,  $61.7 \pm 17.8$  years ( $p$ -value  $< 0.05$ ). Bioprosthesis dysfunction resulted in 16 (5.2%) reoperations due to: fibrocalcific degeneration/rupture (nine), endocarditis (six) or thromboembolism (one). Of the reoperated patients, five received replacements using SJM Biocor™ bovine pericardial bioprosthesis, giving a total of 309 bioprostheses utilized.

Three (0.9%) patients were reoperated for valve replacement using mechanical prosthesis in positions different to the position of the bioprosthesis under study and eleven for the implantation of pacemakers.

Endocarditis was diagnosed in from 1 to 99 months after the operation (mean 27.8 months). Five patients presented endocarditis before the third postoperative month (27.7% of the episodes). The probable cause of infection was identified in five patients (27.7% of the episodes): infection of the urinary tract in three and one case each of oophorectomy and bronchopneumonia. The infectious agent was identified in seven patients: *Enterococcus faecalis* (two), *Staphylococcus epidermis* (two), negative

*Staphylococcus coagulase* (one), *Staphylococcus aureus* (one) and *Pseudomonas aeruginosa* (one). Endocarditis infection resulted in two deaths, six reoperations, one patient continues to be treatment and nine patients responded favorably to the antibiotic therapy.

**Postoperative survival**

The probability of survival for all patients was  $86.3 \pm 3.4\%$  at 5 years and  $69.3 \pm 9.0\%$  at 10 years (Figure 1).

Probabilities of survival of  $90.6 \pm 4.2\%$  and  $81.2 \pm 5.7\%$  at 5 years and  $65.7 \pm 12.4\%$  and  $81.2 \pm 5.7\%$  (p-value < 0.05) at 10 years were observed for female and male patients respectively.

Under 40-year-olds demonstrated a survival rate of  $94.8 \pm 7.1\%$  at 5 years and  $82.0 \pm 13.3\%$  at 9 years; the age group between 40 and 60 years had survival rates of  $85.5 \pm 6.8\%$  over both time intervals: and the over 60-year-old group demonstrated a survival of  $85.6 \pm 4.4\%$  at 5 years and  $58.8 \pm 13.6\%$  at 10 years (Figure 2).

In an investigation concerning the etiology of the valve disease, different survival rates were observed contributing to a lower number of patients in some of the groups. For the

most severe heart diseases (at least 18 patients), the survival rates at 5 and 10 years were  $83.6 \pm 6.2\%$  and  $73.7 \pm 10.7\%$  respectively for idiopathic disease,  $91.5 \pm 5.0\%$  and  $65.5 \pm 14.5\%$  for rheumatic disease,  $83.8 \pm 11.1\%$  at both time intervals for myxomatosis degeneration and  $69.8 \pm 13.9\%$ , again at both time intervals, for ischemic disease.

Patients who underwent mitral valve replacement had lower probability of survival than patients who underwent aortic valve replacement at 5 years ( $81.7 \pm 6.0\%$  and  $87.3 \pm 4.8\%$ ) and 10 years ( $65.1 \pm 10.7\%$  and  $74.8 \pm 9.1\%$ ) - Figure 3.




Fig. 1 – Probability of survival and event free survival




Fig. 2 - Probability of survival, according to age group of patients




Fig 3 - Probability of survival, according to position of implantation

Thus, according to the SI to evaluate the effect of hospital mortality, the results of survival at 5 and 10 years are respectively  $73.3 \pm 2.9\%$  and  $58.9 \pm 7.6\%$ , for the entire sample studied;  $85.3 \pm 6.5\%$  and  $73.8 \pm 12.3\%$  (at 9 years), for under 40-year-olds,  $72.7 \pm 3.8\%$  and  $49.9 \pm 11.5\%$  for over 60-year-olds,  $65.3 \pm 4.2\%$  and  $52.0 \pm 8.0\%$  for patients who underwent mitral valve replacement and  $77.6 \pm 4.8\%$  and  $66.5 \pm 8.6\%$  for those who underwent aortic valve replacement. The SI for patients between 40 and 60 was  $70.9 \pm 5.6\%$  over both time intervals.

**Event-free survival**

The probability of event-free survival was  $77.5 \pm 3.7\%$  at 5 years and  $40.2 \pm 9.0\%$  at 10 years (Figure 1). According to age, the event-free survival of the youngest group (< 40 years) was  $71.7 \pm 10.1\%$  at 5 years and  $27.2 \pm 17.1\%$  at 9 years; for the group between 40 and 60 years it was  $76.4 \pm 7.4\%$  at 5 years and  $39.7 \pm 18.1\%$  at 10 years and for the over 60-year-old group it was  $80.0 \pm 4.6\%$  at 5 years and  $44.3 \pm 11.8\%$  at 10 years (Figure 4). In respect to the position of the bioprosthesis, for patients who were submitted to mitral valve replacement, the event-free survival rate was  $73.6 \pm 6.1\%$  at 5 years and  $38.3 \pm 10.5\%$  at 10 years, while for those who were submitted to aortic valve replacement it was  $78.9 \pm 5.4\%$  and  $56.3 \pm 10.2\%$  for 5 and 10 years respectively (Figure 5).




Fig. 4 - Event free survival according to age group of patients




Fig. 6 - Durability of the bioprosthesis




Fig. 5 - Event free survival, according to position of implantation




Fig. 7 - Durability of the bioprosthesis, according to age group of patients

Considering hospital mortality, the event-free survival rates at 5 and 10 years were  $65.8 \pm 3.1\%$  and  $34.1 \pm 7.6\%$  respectively for the entire sample;  $64.5 \pm 9.0\%$  and  $24.4 \pm 15.3\%$  (at 9 years) for under 40-year-olds,  $63.4 \pm 6.1\%$  and  $32.9 \pm 15.0\%$  for patients between 40 and 60 years,  $68.0 \pm 3.9\%$  and  $37.6 \pm 10.0\%$  for over 60-year-olds;  $58.8 \pm 4.9\%$  and  $30.6 \pm 8.4\%$  for patients submitted to mitral valve replacement and  $70.2 \pm 4.8\%$  and  $50.1 \pm 9.1\%$  for patients submitted to aortic valve replacement.

**Bioprosthesis durability**

The estimation of the bioprosthesis durability was  $87.8 \pm 2.5\%$  at 5 years and  $57.7 \pm 9.9\%$  at 10 years (Figure 6). Considering the effect of age, the estimated durability to the implantations in the youngest patients (< 40 years) was  $76.7 \pm 8.5\%$  at 5 years and  $34.5 \pm 20.7\%$  at 9 years. For patients between 40 and 60 years and for those with ages greater than 60 years, the estimation was  $83.2 \pm 5.7\%$  and  $93.1 \pm 2.2\%$  and  $43.2 \pm 19.5\%$  and  $75.8 \pm 9.7\%$  for the corresponding time intervals (Figure 7).




Fig. 8 - Durability of the bioprosthesis, according to position of implantation

The estimation of aortic bioprosthesis durability was  $89.2 \pm 3.5\%$  at 5 years and  $75.4 \pm 9.4\%$  at 10 years. For mitral valve bioprostheses, the durability was  $85.4 \pm 4.4\%$  and  $57.0 \pm 11.7\%$  respectively (Figure 8).

The probability of structural failure for all bioprostheses was 5% over 5 years and 20% over 10 years. For bioprosthesis in the aortic position, the probability of structural failure was zero and 8% over the same time intervals.

#### Change in the functional class

In recent follow-ups, 88.5% of the patients were in functional class I, 9.1% in class II and 2.3% in class III, demonstrating a significant improvement from the preoperative period ( $p$ -value  $< 0.05$ ).

#### COMMENTS

Due to the large numbers of available replacement valves, the performance of the different prostheses over time is very important in the choice of the best valve for implantation. This study shows the results of the implantation of SJM-Biocor™ bovine pericardial bioprosthesis in patients with heart valve disease comparing them with the results in the literature [18-21].

As the main goal of the study is an analysis of the long-term survival of patients, as well as events related to the bioprosthesis, survival curves were calculated from hospital discharge, as the factors determining immediate mortality are mainly related to the clinical condition of the patient and to the surgical procedure, in detriment of the hemodynamic performance and possible complications of the bioprosthesis [22-26].

The mortality rate of 9.2% over 10 years of follow-up is acceptable, as there have been rates of up to 46% reported [19,20,27]. As many variables can contribute to late deaths or influence the absolute number of deaths (patients exposed to risks each year, follow-up time), the causes of death must be considered. Five deaths related to bioprostheses occurred (17.8% of the total), as a consequence of endocarditis, structural dysfunction and thromboembolism, a finding similar to a reported 22% [18]. In this series of patients, 56% of the late deaths were caused by heart problems, a number greater than in our investigation (25%). This difference may be justified by the high rate of deaths due to unknown causes in our series. It is relevant that failure of the prosthesis resulted in only a few deaths.

The probability of survival for all the patients in our series was  $86.3 \pm 3.4\%$  at 5 years and  $69.3 \pm 9.0\%$  at 10 years, while other authors reported rates of from 46% to 71% for this interval [18,20,21]. The estimation of event-free survival was low ( $40.2 \pm 9.0\%$  over 10 years), a fact which was also observed in patients with other types of bioprosthesis [28,29], and attributable to factors such as age of the patients, severity of the heart disease, position of the implanted prosthesis and postoperative prophylaxis for endocarditis and thromboembolism.

One factor to be considered is related to the age of the patients. For under 40-year-old patients, the probability of survival over 9 years was  $82.0 \pm 13.3\%$ , while event-free survival was only  $27.2 \pm 17.1\%$ . A significant difference between actuarial and event-free survival is expected in this population as patients in this age group present with a greater number of complications related to the bioprosthesis, particularly fibrocalcific degeneration [30,31].

The satisfactory expectation of survival can be explained by an effective neutralization of complications (such as low mortality in reoperations for valve dysfunction and curative clinical treatment of endocarditis). A similar result was obtained with patients of the intermediary age group: actuarial survival of  $85.5 \pm 6.8\%$  both at 5 and 10 years and event-free survival of  $76.4 \pm 7.4\%$  and  $39.7 \pm 18.1\%$ , respectively. The survival of over 60-year-old patients was  $85.6 \pm 4.4\%$  at 5 years and  $58.8 \pm 13.6\%$  over 9 years, percentages that are partially justified by the advanced age and by the terminal repercussions of heart disease (and systemic diseases). Event-free survival was similar to the actuarial survival in both time intervals ( $80.0 \pm 4.6\%$  and  $44.4 \pm 11.8\%$ , respectively), showing few non-fatal events. These findings endorse the use of bioprosthesis in elderly patients [20,21,31].

The probability of survival in respect to subjacent heart disease was variable (Figure 4), with more favorable results in patients with myxomatous and idiopathic heart diseases. The reduced number of patients in some groups hinders a clear understanding of the effect of subjacent heart diseases on actuarial and event-free survival.

The estimation of survival in relation to the position of the bioprosthesis has been the subject of many studies. Our results for patients who were submitted to aortic valve replacement show a survival rate of  $74.8 \pm 9.1\%$  at 10 years. Patients with 2<sup>nd</sup>-generation Carpentier-Edwards bovine pericardial bioprostheses present with very similar expected survival rates, with values of from 40% to 70%, over 10 years [21,22,31] and from 34% to 53% over 12 years of follow-up [19,20,32]; some studies with lower estimations include operative mortality. In our series, patients who underwent mitral valve replacement had a lower survival rate when compared with patients after aortic valve replacement,  $65.1 \pm 10.7\%$  at 10 years. Publications report expected survival rates of between 62% to 73% at 8 years, 57% over 10 years, 54% in the 12<sup>th</sup> and 37% in the 15<sup>th</sup> year [18,21,31,32].

For the period of 10 years, the follow-up time of our study, SJM-Biocor™ bioprostheses maintained a performance similar to Carpentier-Edwards bioprostheses both in the aortic and mitral positions and we conjecture results comparable over longer follow-up times, but this needs to be confirmed with future investigations.

In respect to morbidity, the prevalence of endocarditis was 5.9% and resulted in six reoperations (38% of the

explanted bioprosthesis) and two deaths (7.1% of the total deaths). In spite of being recognized as a common cause of death [18,20], bioprosthesis dysfunction (prevalence from 4.2% to 6.8%) [20,21,27] or reoperation (responsible from 6.3% to 13% of the explanted bioprosthesis) [20,27,33], the prevalence of endocarditis should be considered as high. Taking into consideration the patients exposed to risk, the literature shows an incidence of endocarditis of from 0.4% to 2.4% per patient-year [13,34], while in our series we observed a rate of 1.9% per patient-year.

The mean time between bioprosthesis implantation and the start of endocarditis was 25 months (ranging from 2 to 99 months). The occurrence of four infections within the first 3 postoperative months and the identification of a probable entry point in five patients are significant. If a second episode of endocarditis in one patient, 2 months after the first, were included in this last observation, more than 50% of the cases would have the cause defined as not related to the prosthesis. However, patients must be counseled on prophylactic antibiotic treatment. Also, a consequent response should be expected if endocarditis were suspected (or confirmed by blood cultures).

Structural failure resulted in one death and nine reoperations; as 15 patients presented with this complication, six patients with diagnoses of prosthetic failure remained under clinical observation waiting for reoperations. When diagnosis is established, the urgency for reoperation depends on the clinical condition of the patient, on the degree of failure and on the characteristics of the patient.

Structural failure is an important determining factor of the performance of the bioprosthesis. The durability of the bioprostheses was estimated at  $75.4 \pm 9.4\%$  over 10 years in the aortic position and  $57.0 \pm 11.7\%$  in the mitral position. In the literature, for patients who undergo aortic valve replacement, the estimated freedom from structural deterioration, equivalent to durability, has been reported as being between 91% and 100% over 10 years and 82% and 100% over 12 years [19,20,32,35]. For Carpentier-Edwards mitral bioprostheses the values were 76% over 10 years [18] and 78% over 12 years [36]. The age affects the durability of the bioprosthesis, as younger patients present lower values than the older population [33]. The probability of structural failure for all bioprosthesis was 5% over 5 years and 20% over 10 years. For aortic bioprosthesis the results were better, with an estimation of zero and 8% for the same time intervals. Even so the performance of the aortic bioprosthesis is highly satisfactory.

Prosthesis failure due to fibrocalcific degeneration or rupture is a serious concern when bioprosthesis implantation is considered. These events are mainly related to the quality and to the treatment of the biological tissue [6,34] and with the age of the patient [21,25]. Rupture specifically refers to the design of the bioprosthesis and its assembling [6,10].

As in the production of the current generation of bioprosthesis, including the SJM-Biocor™, special attention is paid to the hemodynamic performance and to the mechanical durability, as well as to the project and assembling of bovine pericardial membrane (including the internal lining); failures due to the project and to assembling of bioprostheses are few. Structural deterioration is mainly related to the age of the patient and evidence of low incidences or even no fibrocalcific degeneration in older populations has been reported in publications [18,20,31].

The mean age of patients with fibrocalcific degeneration was significantly lower than the mean age of the patients without this complication, showing that this complication is more common in younger individuals. The prevalence of structural dysfunction was 4.9% in our series, lower than the 1.7% seen in a series of patients who underwent aortic and mitral valve replacements followed up over a period of 12 years [29], but comparable with individual series of patients submitted to mitral (from 2.1% to 2.7%) and aortic valve (up to 8.2%) replacements [19,20]. For a follow-up period of up to 15 years, cases of dysfunction increased to 12.4% for mitral bioprosthesis implantation [33].

Thromboembolism was identified in three (0.9%) patients and was a possible cause of death in two others who suffered cerebrovascular ischemia. Another patient had to be submitted to a reoperation for mitral bioprosthesis replacement due to thrombosis both of the atrium and bioprosthesis. These events, also observed in other series [18,20,21,33], show that some patients undergoing valve replacement with bioprostheses, additional to those with recognized indications, which include patients with chronic atrial fibrillation, enlarged left atrium or concomitant mechanical prosthesis, must receive prophylactic anticoagulation. There are studies of patients with pericardial bioprosthesis that demonstrate a similar number of events caused by bleeding complications related to anticoagulant therapy and episodes of thromboembolism [20]. Because of this, we take special care to consider the evolution of individual patients before indicating oral anticoagulation.

Combining our results with published results, it is obvious that the main indication of bioprosthesis implantation is to replace aortic valves in over 60-year-old patients, as the risk of prosthesis failure is low [1,20,27]. The results of elderly patients who undergo mitral valve replacement are also expected to be good [18,33,34]. Young patients (under 40-year-olds) present a high probability of failure over a long term with the necessity of reoperations. The implantation of a bioprosthesis must be indicated if a mechanical apparatus can not be utilized, due to intellectual, social or economical reasons. Women who wish to become pregnant also require the implantation of a bioprosthesis and in these circumstances our results indicate that the SJM-Biocor™ may be considered.

The clinical condition of patients is an indirect measurement of the hemodynamical performance of bioprostheses. It was observed that 97.6% of the patients with recent follow-ups are in functional classes I or II (NYHA), a result similar to those described in the literature [27,29,32,36]. The hemodynamical performance of SJM-Biocor™ bioprostheses was the subject of pulse simulating tests demonstrating an adequate result [6]. It is important to emphasize that in this series there were no cases of valve replacement due to flow obstruction (stenosis) with normally functioning bioprostheses.

#### CONCLUSION

This study presents some limitations, such as the small sample size of subgroups (mainly in groups with an etiology of heart disease and in the younger age group) and with the 10 years of complete follow-up. However, our results are comparable to findings reported in other publications on 2<sup>nd</sup>-generation bovine pericardial bioprosthesis available on the market and guarantee the quality of SJM-Biocor™ bioprostheses for heart valve replacement.

#### ACKNOWLEDGMENT

The current study was partially supported with help offered to Dr. João Ricardo Michielin Sant'Anna by the Brazilian National Research Counsel (CNPq).

#### BIBLIOGRAPHIC REFERENCES

1. Birkmeyer NJ, Birkmeyer JD, Tosteson AN, Grunkemeier GL, Marrin CA, O'Connor GT. Prosthetic valve type for patients undergoing aortic valve replacement: a decision analysis. *Ann Thorac Surg.* 2000;70(6):1946-52.
2. Wallace RB. Tissue valves. *Am J Cardiol.* 1975;35(6):866-71.
3. Jones EL, Craver JM, Morris DC, King III SB, Douglas Jr JS, Franch RH et al. Hemodynamic and clinical evaluation of the Hancock xenograft bioprosthesis for aortic valve replacement (with emphasis on management of the small aortic root). *J Thorac Cardiovasc Surg.* 1978;75(2):300-8.
4. Fantini FA, Vrandecic MO, Gontijo Filho B, Oliveira OC, Martins Jr IC, Marinho AA et al. Biopróteses aórticas porcinas, modelo convencional e sem suporte ("stentless"): estudo comparativo. *Rev Bras Cir Cardiovasc.* 1998;13(3):221-8.
5. Pomerantzeff PMA, Brandão CMA, Braile DM, Albuquerque JMAC, Ramirez VDA, Camim A et al. Novo conceito de bioprótese: bioprótese com descontinuidade do anel de sustentação (less stented)®. *Rev Bras Cir Cardiovasc.* 2004;19(3):267-73.
6. Carpentier A, Dubost C, Lane E, Nashef A, Carpentier S, Relland J et al. Continuing improvements in valvular bioprostheses. *J Thorac Cardiovasc Surg.* 1982;83(1):27-42.
7. Rossiter SJ, Miller DC, Stinson EB, Oyer PE, Reitz BA, Moreno-Cabral RJ et al. Hemodynamic and clinical comparison of the Hancock modified orifice and standard orifice bioprostheses in the aortic position. *J Thorac Cardiovasc Surg.* 1980;80(1):54-60.
8. Ionescu MI, Tandon AP, Mary DA, Abid A. Heart valve replacement with the Ionescu-Shiley pericardial xenograft. *J Thorac Cardiovasc Surg.* 1977;73(1):31-42.
9. Braile DM, Volpe MA, Ramin SL, Souza DRS. Tratamento cirúrgico das valvopatias. Parte 1. *Rev Bras Cir Cardiovasc.* 1994;9(2):113-22.
10. Gabay S, Bortulotti U, Wasserman F, Factor SM. Hemodynamics and durability of mitral bioprostheses: an in vitro study. *Eur Heart J.* 1984;5(Suppl D):65-71.
11. Jamieson WR, Pelletier LC, Janusz MT, Chaitman BR, Tyers FO, Miyagishima RT. Five-year evaluation of the Carpentier-Edwards porcine bioprosthesis. *J Thorac Cardiovasc Surg.* 1984;88(3):324-33.
12. Grunkemeier GL, Bodnar E. comparative assessment of bioprosthesis durability in the aortic position. *J Heart Valve Dis.* 1995;4(1):49-55.
13. Braile DM, Ardito RV, Greco OT, Lorga AM. IMC Bovine pericardial valve: 11 years. *J Card Surg.* 1991;6(4 suppl):580-8.
14. Vrandecic MO, Gontijo BF, Silva JAP, Fantini FA, Barbosa JT. Estudo multicêntrico dos resultados das trocas valvares com o uso da bioprótese Biocor no Estado de Minas Gerais. *Rev Bras Cir Cardiovasc.* 1988;3(3):159-68.
15. Bonow RO, Carabello B, de Leon Jr AC, Edmunds Jr LH, Fedderly BJ, Freed MD et al. Guidelines for the management of patients with valvular heart disease: executive summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease). *Circulation.* 1998;98(18):1949-84.
16. Edmunds Jr LH, Clark RE, Cohn LH, Grunkemeier GL, Miller DC, Weisel RD. Guidelines for reporting morbidity and mortality after cardiac valvular operations. The American Association for Thoracic Surgery, Ad Hoc Liaison Committee for Standardizing Definitions of Prosthetic Heart Valve Morbidity. *Ann Thorac Surg.* 1996;62(3):932-5.



17. Grunkemeier GL, Jamieson WR, Miller DC, Starr A. Actuarial vs actual risk of porcine structural valve deterioration. *J Thorac Cardiovasc Surg.* 1994;108(4):709-18.
18. Aupart MR, Neville PH, Hammami S, Sirinelli AL, Meurisse YA, Marchand MA. Carpentier-Edwards pericardial valves in the mitral position: ten-year follow-up. *J Thorac Cardiovasc Surg.* 1997;113(3):492-8.
19. Dellgren G, David TE, Raanani E, Armstrong S, Ivanov J, Rakowski H. Late Hemodynamic and clinical outcomes of aortic valve replacement with the Carpentier-Edwards Perimount pericardial bioprosthesis. *J Thorac Cardiovasc Surg.* 2002;124(1):146-54.
20. Banbury MC, Cosgrove III DM, Lytle BW, Smedira NG, Sabik JF, Saunders CR. Long-term results of the Carpentier-Edwards pericardial aortic valve: a 12-year follow-up. *Ann Thorac Surg.* 1998;66(6 suppl):S73-6.
21. Pelletier LC, Carrier M, Leclerc Y, Dyrda I. The Carpentier-Edwards pericardial bioprosthesis: clinical experience with 600 patients. *Ann Thorac Surg.* 1995;60(2 suppl):S297-302.
22. Hannan EL, Racz MJ, Jones RH, Gold JP, Ryan TJ, Hafner JP et al. Predictors of mortality for patients undergoing cardiac valve replacement in New York State. *Ann Thorac Surg.* 2000;70(4):1212-8.
23. Ambler G, Omar RZ, Royson P, Kinsman R, Keogh BE, Taylor KM. Generic, simple risk stratification model for heart valve surgery. *Circulation.* 2005;112(2):224-31.
24. Jamieson WR, Edwards FH, Schwartz M, Bero JW, Clark RE, Grover FL. Risk stratification for cardiac valve replacement. National Cardiac Surgery Database. Database Committee of the Society of Thoracic Surgeons. *Ann Thorac Surg.* 1999; 67(4):943-51.
25. Jin R, Grunkemeier GL, Starr A. Validation and refinement of mortality risk models for heart valve surgery. Providence Health System Cardiovascular Study Group. *Ann Thorac Surg.* 2005;80(2):471-9.
26. Edwards MB, Taylor KM. Is 30-day mortality an adequate outcome statistic for patients considering heart valve replacement? *Ann Thorac Surg.* 2003;76(2):482-6.
27. Perier P, Mihaileanu S, Fabiani JN, Deloche A, Chauvaud S, Jindani A et al. Long-term evaluation of the Carpentier-Edwards pericardial valve in the aortic position. *J Card Surg.* 1991;6(4 suppl):589-94
28. Cohn LH, Collins Jr JJ, Rizzo RJ, Adams DH, Couper GS, Aranki SF. Twenty-year follow-up with the Hancock porcine xenograft in the elderly. *Ann Thorac Surg.* 1998;66(6Suppl):S35-9.
29. Grunkemeier GL, Bodnar E. Comparison of structural valve failure among different 'models' of homograft valves. *J Heart Valve Dis.* 1994;3(3):556-60.
30. Cosgrove DM, Lytle BW, Taylor PC, Camcho MT, Stewart RW, McCarthy PM et al. The Carpentier-Edwards pericardial aortic valve: ten-year results. *J Thorac Cardiovasc Surg.* 1995;110(3):651-62.
31. Aupart MR, Dreyfus XB, Meurisse YA, Rouchet SC, Sirinelli AL, May MD et al. The influence of age on valve related events with Carpentier-Edwards pericardial valves. *J Cardiovasc Surg.* 1995;36(4):297-302.
32. Neville PH, Aupart MR, Diemont FF, Sirinelli AL, Lemoine EM, Marchand MA. Carpentier-Edwards pericardial bioprosthesis in aortic or mitral position: a 12-year experience. *Ann Thorac Surg.* 1998;66(6 suppl):S143-47.
33. Marchand MA, Aupart MR, Norton R, Goldsmith IRA, Pelletier LC, Pellerin M et al. Fifteen-year experience with the mitral Carpentier-Edwards PERIMOUNT pericardial bioprosthesis. *Ann Thorac Surg.* 2001;71(5 suppl):S236-9.
34. Carpentier A, Lemaigre G, Robert L, Carpentier S, Dubost C. Biological factors affecting long-term results of valvular heterografts. *J Thorac Cardiovasc Surg.* 1969;58(4):467-83.
35. Poirer NC, Pelletier LC, Pellerin M, Carrier M. 15-year experience with the Carpentier-Edwards pericardial bioprosthesis. *Ann Thorac Surg.* 1988;66(6 Suppl):S57-61.
36. Dellgren G, David TE, Raanani E, Armstrong S, Ivanov J, Rakowski H. Late hemodynamic and clinical outcomes of aortic valve replacement with the Carpentier-Edwards Perimount pericardial bioprosthesis. *J Thorac Cardiovasc Surg.* 2002;124(1):146-54.